Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

In the latest close session, Boston Scientific (BSX) was down 1.84% at $42.68. The stock's change was less than the S&P 500's daily gain of 0.79%. Meanwhile, the Dow gained 0.26%, and the Nasdaq, a tech-heavy index, added 1.52%. The stock of medical device manufacturer has fallen by 9.38% in the past month, lagging the Medical sector's gain of 7.53% and the S&P 500's loss of 1.82%.The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. In that report, analysts expect Boston Scientific to post earnings of $0.83 per share. This would mark year-over-year growth of 10.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $5.39 billion, indicating a 6.54% increase compared to the same quarter of the previous year. BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.36 per share and revenue of $21.61 billion. These results would represent year-over-year changes of +9.8% and +7.65%, respectively. Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.37% fall in the Zacks Consensus EPS estimate. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell). Looking at its valuation, Boston Scientific is holding a Forward P/E ratio of 12.95. Its industry sports an average Forward P/E of 18.39, so one might conclude that Boston Scientific is trading at a discount comparatively. We can also see that BSX currently has a PEG ratio of 0.83. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry had an average PEG ratio of 1.65 as trading concluded yesterday. The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 180, positioning it in the bottom 27% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks